-
Mashup Score: 1
Anna Azvolinsky is a science and health journalist based in New York City. A new clinical trial has found that a 30-minute intravenous (IV) infusion of isatuximab for patients with newly diagnosed multiple myeloma (NDMM) is safe and feasible, providing ease for patients and oncology institutions. The results of the phase Ib study were published in HemaSphere. 1 Isatuximab is a CD38-directed cytolytic antibody that is approved by the U.S. Food and Drug Administration for patients with MM, in combination
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Relapse-Free Survival Progressively Shortens in Black Patients With Rituximab-Treated iTTP | ASH Clinical News | American Society of Hematology - 13 day(s) ago
Katie Robinson is a medical writer based in New York. In patients with relapsing immune thrombotic thrombocytopenic purpura (iTTP), successive rituximab treatment shortens relapse-free survival (RFS), a finding most pronounced in Black patients, who comprise most of the individuals in the U.S. with this chronically relapsing disorder. These findings were published in Blood Advances. “We identified that there is a subgroup of mostly (self-identified) Black patients with iTTP who have shorter and shorter
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
In patients with relapsing #iTTP, successive treatment with #rituximab was found to shorten relapse-free survival, which was most pronounced in Black patients, who comprise most of the individuals in the U.S. with the disorder: https://t.co/c2kPCmi7TC
-
-
Mashup Score: 7
February 2025 | ASH Clinical News | American Society of Hematology February 2025 Thrown into Disarray The sudden withdrawal of voxelotor from the market left physicians and patients scrambling for answers and reverting to older treatments for sickle cell disease. Viewpoints Editor’s Corner “Scope Creep” Debate Between AMA, AAPA Fails to Put Patients First Advanced Practitioner Voices Many Factors Contribute…
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
The February issue is out now! 🩸 Issue highlights include features on the withdrawal of #voxelotor for #SickleCellDisease, #burnout among #AdvancedPracticeProviders, and more. Check out the full lineup here: https://t.co/R0vPDKUOec https://t.co/NyyYcnbuQF
-
-
Mashup Score: 0Anxiety, Depression Elevated in Patients with Histiocytic Neoplasms | ASH Clinical News | American Society of Hematology - 19 day(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. While previous research has documented high levels of anxiety and depression in patients with cancer, mood disorders have not been systematically studied in patients with histiocytic neoplasms (HN). Research indicates that one in three patients with HN has anxiety and depression, which is stable over time and correlated with financial burden, symptom severity, and health-related quality of life (HRQoL). Anne S. Reiner, MPH, a senior
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Findings from a recent systemic study indicate that one in three patients with #HistiocyticNeoplasms has #anxiety and #depression, which is stable over time and correlated with financial burden, symptom severity, and health-related quality of life: https://t.co/soVD9jYPeF
-
-
Mashup Score: 0ASH Clinical News: February 2025 From the Desk Of... - 25 day(s) ago
Editor-in-Chief Aaron Gerds, MD, previews what’s to come in ASH Clinical News. Highlights of the February issue include a feature on the recent withdrawal of…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Preview the February issue with @AaronGerds! Highlights of this issue include a feature on the recent withdrawal of #voxelotor for #SCD and the effect on patients, a look at the publishing landscape in #LMICs, an editorial on #ScopeCreep, and more: https://t.co/dGntGiMsir
-
-
Mashup Score: 0R/R ALL Treatment Receives FDA Approval | ASH Clinical News | American Society of Hematology - 27 day(s) ago
Obecabtagene autoleucel received approval from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL) in adults. The medication is a CD19-directed genetically modified autologous T-cell immunotherap y. The treatment’s efficacy was evaluated in an open-label, multicenter, single-arm trial dubbed FELIX, in which 42% of patients achieved a complete remission within three months. Common adverse reactions included
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
In late 2024, #ObecabtageneAutoleucel, a CD19-directed T-cell immunotherapy, received #FDA approval for the treatment of R/R B-cell ALL following the FELIX study, in which 42% of patients achieved a complete remission within three months: https://t.co/pKPAFW85tr
-
-
Mashup Score: 0Oral Solution Imatinib Receives FDA Approval for Several Hematologic Diseases | ASH Clinical News | American Society of Hematology - 30 day(s) ago
Imatinib oral solution received U.S. Food and Drug Administration (FDA) approval for the treatment of chronic myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes/myeloproliferative neoplasms. The treatment is a tyrosine kinase inhibitor previously approved to treat hypereosinophilic syndrome and chronic eosinophilic leukemia as well as other types of cancer. It is a strawberry-flavored oral solution. “We are thrilled to offer an oral solution option for patients with leukemia
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
In late November, the #FDA approved oral solution #imatinib for the treatment of several blood #cancers, including CML, ALL, and MDS/MPN, ultimately allowing for more precise and consistent dosing: https://t.co/AqXRWoJVin
-
-
Mashup Score: 1January 2025 | ASH Clinical News | American Society of Hematology - 1 month(s) ago
January 2025 | ASH Clinical News | American Society of Hematology January 2025 Health Care Handcuffed? The overturning of the Chevron doctrine, a decades-old precedent, opens the door to legal challenges affecting health care agencies and, ultimately, patient care. Viewpoints Editor’s Corner Ms. Cellophane: How Clinical Research Looks Right Through People with Child-Bearing Potential Education You Make the Call You…
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Our January issue is out now! In addition to recap from #ASH24, highlights of this issue include articles on the overturning of the #Chevron doctrine, post-transplant BKV-related #hemorrhagic #cystitis in children, and more. Check out the full lineup at https://t.co/5uwagK7UBq https://t.co/0evBI7IfX8
-
-
Mashup Score: 0MGUS Risk Assessment Over Time Yields Benefits, Study Shows | ASH Clinical News | American Society of Hematology - 1 month(s) ago
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. Using models to measure the progression risk of patients with monoclonal gammopathy of undetermined significance (MGUS) over time improves the assessment of risk of progression to smoldering multiple myeloma and multiple myeloma, according to findings published in Blood Cancer Journal. The retrospective study by a research group in Germany shows the value of regular MGUS measuring, which has become the regular practice of
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Using models to measure the progression of patients with #MGUS over time improved assessment of the risk of progression to #SMM and #MMsm, with patients who were upstaged to a higher-risk category having an increased risk of progression: https://t.co/zAoDOrLkUS
-
-
Mashup Score: 1Discontinuing Maintenance Therapy for Multiple Myeloma Is Feasible, New Study Shows | ASH Clinical News | American Society of Hematology - 1 month(s) ago
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. Patients with multiple myeloma (MM) who discontinued maintenance therapy based on measurable residual disease (MRD) negativity had a high rate of sustained MRD negativity without disease progression, according to the results of a prospective trial. The MRD2STOP study demonstrated that patients with MRD negativity at the 10 -6 threshold (less than one myeloma cell within one million cells analyzed) at the time of
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
According to the results of the prospective MRD2STOP trials, patients with #MultipleMyeloma #MM who discontinued maintenance therapy based on MRD negativity experienced a high rate of sustained MRD negativity without disease progression: https://t.co/XvZZTzPipP
-
According to a recent phase 1b study, a 30-minute IV infusion of #isatuximab in patients with newly diagnosed #MultipleMyeloma is safe, with only one instance of infusion reaction, and is more feasible than the standard 75-minute infusion dose: https://t.co/GVH3cRkEoY